Literature DB >> 16632187

Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?

Martin C Schumacher1, Fiona C Burkhard, George N Thalmann, Achim Fleischmann, Urs E Studer.   

Abstract

OBJECTIVE: Controversy persists concerning the role of pelvic lymph node dissection (PLND) in patients with preoperative PSA values <10ng/ml undergoing treatment for prostate cancer with a curative intent. The aim of this study was to determine the incidence of lymph node metastasis in this subgroup of patients.
METHODS: Patients with clinically localized prostate cancer and a serum PSA<10ng/ml, without neoadjuvant hormonal or radiotherapy, with negative staging examinations who underwent radical retropubic prostatectomy with bilateral extended PLND and with >/=10 lymph nodes detected by the pathologist in the surgical specimen, were included in the study.
RESULTS: A total of 231 patients with a median serum PSA of 6.7ng/ml (range 0.4-9.98) and a median age of 62 years (range 44-76) were evaluated. A median of 20 (range 10-72) nodes were removed per patient. Positive nodes were found in 26 of 231 patients (11%), the majority of which (81%) had a Gleason score >/=7 in the surgical specimen. Of the patients with a Gleason score >/=7 in the prostatectomy specimen 25% had positive nodes, whereas only 3% with a Gleason score </=6 were node positive.
CONCLUSIONS: The incidence of positive nodes in patients with clinically localized prostate cancer, a serum PSA<10ng/ml and a Gleason score >/=7 in the prostatectomy specimen was 25% after extended PLND. It seems that in this patient group extended PLND, including removal of nodes along the internal iliac vessels, is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16632187     DOI: 10.1016/j.eururo.2006.01.061

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  23 in total

1.  Why all prostate cancer surgery should include an adequate lymph node dissection.

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

2.  Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Authors:  Hillary M Ross; Oleksandr N Kryvenko; Janet E Cowan; Jeffry P Simko; Thomas M Wheeler; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

3.  [Seminal vesicle sparing radical perineal prostatectomy].

Authors:  S Schäfers; P de Geeter; H Löhmer; P Albers
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

4.  Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.

Authors:  Christian von Bodman; Guilherme Godoy; Daher C Chade; Angel Cronin; Laura J Tafe; Samson W Fine; Vincent Laudone; Peter T Scardino; James A Eastham
Journal:  J Urol       Date:  2010-05-15       Impact factor: 7.450

Review 5.  Sentinel node evaluation in prostate cancer.

Authors:  Ramkishen Narayanan; Timothy G Wilson
Journal:  Clin Exp Metastasis       Date:  2018-09-05       Impact factor: 5.150

Review 6.  Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.

Authors:  Gilles Créhange; Chien Peter Chen; Charles C Hsu; Norbert Kased; Fergus V Coakley; John Kurhanewicz; Mack Roach
Journal:  Cancer Treat Rev       Date:  2012-06-15       Impact factor: 12.111

7.  [Value of lymphadenectomy for limited nodal recurrence of prostate cancer after local therapy with curative intent].

Authors:  I Wolff; M-O Grimm; M Wirth
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

Review 8.  DW-MRI of the urogenital tract: applications in oncology.

Authors:  G Petralia; H C Thoeny
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909

Review 9.  Extended lymph node dissection for prostate cancer.

Authors:  Stephan Jeschke; Fiona C Burkhard; Ramesh Thurairaja; Nivedita Dhar; Urs E Studer
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

10.  Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.

Authors:  Daniela B Husarik; Raymond Miralbell; Markus Dubs; Hubert John; Olivier T Giger; Albert Gelet; Tibor Cservenyàk; Thomas F Hany
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.